The company said revenue in the year to date will be broadly in line with last year after adjusting for unprofitable business streams that have been terminated.
“Consistent with the widely reported conditions on the UK high street, the business has experienced a reduction in store footfall during the period compared to the previous year when the group experienced particularly strong demand,” it said.
The group added: “Whilst trading conditions are expected to remain difficult, the board continues to believe that, through the strength of Quiz’s flexible business model and increasing online focus, the group can return to sustainable profitable growth in the medium term.”
Just Group PLC (LON:JUST) shares slid 8.6% to 42.30p as the retirement products firm abandoned a plan to reinstate its dividend for the 2019 financial year, blaming regulatory and economic uncertainty.
The company, formerly known as Just Retirement Group plc, ditched the dividend as it revealed profit fell more than a quarter in the first half on the back of a sharp fall in new business.
Underlying operating profit fell 27% to £114mln due to a 39% decrease in new business operating profit to £74mln.
The data is from a phase 2a trial of the company’s Milciclib monotherapy in patients who are resistant or intolerant to the Sorafenib drug for treating metastatic hepatocellular carcinoma, a cancer that usually spreads to lungs, lymph nodes, adrenal gland and bones, including the skull.
In July, Tiziana reported that clinical data from the trial indicated that Milciclib was well tolerated with manageable toxicities and no recorded drug-related deaths, thereby meeting the trial’s primary endpoint.
In Wednesday’s update, the group revealed the trial also met its secondary endpoints including progression-free survival and time to progression.
The energy consultant to UK and Irish firms said profit before tax rose to £3.23mln in the six months to the end of June from £2.09mln a year ago as revenue rose 33% to £21.56mln. The growth was led by its corporate division, which grew its order book to £55.4mln from £53.0mln last year.